Markets Book Profits as Q4 Earnings Season Gets Rolling

Major U.S. indexes were mostly flat with the Dow falling 398 points (-0.80%), the S&P 500 down 13 points (-0.19%), and the Nasdaq and Russell 2000 off ~0.1%; JPMorgan slid ~4% despite reported better-than-expected Q4 results. Positive company-specific moves included Moderna up ~17% after approval of a Covid-flu hybrid vaccine and Intel rallying ~7% (intraday +10%) on hyperscaler demand and a KeyBanc upgrade, with AMD also strong amid the AI trade. Key economic reads showed CPI beating expectations earlier, New Home Sales (October) at 737K SAAR vs 710K projected (738K prior), and the December budget deficit narrowing to -$144.7B vs -$150B expected. Market focus shifts to bank Q4 results (Citigroup, BAC, Wells Fargo showing expected EPS growth of +23%, +15.8% and +17%), and delayed November data due tomorrow including PPI, Retail Sales, Existing Home Sales and the Beige Book.

Analysis

Market structure: AI/semiconductor hyperscaler demand is the clear winner — INTC and AMD show durable order flow and price power in 2026; Moderna’s vaccine approval creates near-term revenue upside for MRNA but with execution risk. Banks are the losers in the very near term (JPM -4%) as market discounts trading and credit volatility into Q4 prints; housing and a shrinking deficit mildly support cyclical reflation but not enough to offset bank-specific guidance risk.

Risk assessment: Tail risks include a Supreme Court tariff reversal that meaningfully raises input costs and reverses the fiscal improvement narrative, a Fed pivot if PPI/retail surprise hot (PPI MoM >+0.4%), or a concentrated AI demand pullback if hyperscalers cut capex by >10% QoQ. Immediate (days): elevated earnings-driven volatility in banks; short-term (weeks–months): guidance-driven re-rating across semis; long-term (quarters–years): structural AI revenue growth but margin and competition risk.

Trade implications: Prefer reallocation from bank beta into high-conviction semi/AI exposure: size disciplined long positions in INTC/AMD and hedge with protective puts; use call spreads to limit premium on upside. For banks, either sharply reduce gross exposure ahead of Citigroup/BAC/WFC prints or hedge with short-dated OTM puts sized to expected earnings gap; expect a 5–15% move range around earnings.

Contrarian angle: The market may be underpricing bank resilience if credit metrics hold — a worse-than-feared headline could reverse quickly; conversely AI names are at risk of overshooting on upgrade momentum (watch order-book cadence). Historical parallels: 2019–20 tech re-rates show rapid consensus compression after a single big capex re-acceleration; watch sequencing (earnings then macro) which will drive dispersion.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in INTC and a 1.5–2% long in AMD within 10 trading days; add another 1–2% to INTC on any pullback >5% from entry. Target 20–35% upside by Q3 2026; hard stop-loss at -12% per position.
• Trim financials exposure by 50% from benchmark weight ahead of Citi (C), BAC and WFC prints (next 48–72 hours). Replace with the INTC/AMD allocation above; if banks report earnings misses, purchase 3-month puts sized to 0.5% portfolio risk (example: buy JPM 3M 10% OTM puts) to hedge remaining exposure.
• Buy limited-risk call spreads on INTC: Mar-2026 45/60 call spread (size 0.75% portfolio) to capture upside while capping premium; roll or take profits if spread value doubles or by Sept 1, 2026.
• Allocate 1–1.5% to MRNA after sizing regulatory rollout risk: enter on any <10% post-approval retracement. Target 25–40% by end-2026; stop at -25%.
• Monitor PPI and Retail Sales releases (tomorrow): if PPI MoM >+0.4% or Retail Sales miss by >1% versus consensus, pause new long semi positions and add 0.5% duration to Treasury holdings (buy 2–5yr) as a tactical hedge.